Gabriel Brooks - 13 Feb 2026 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Reporting relationship: Chief Medical Officer
Issuer ticker: SLDB
Reported as of: 13 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Feb 2026, 21:28:37 UTC
Prior SEC filing: 06 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Kimberly Cornwell as attorney-in-fact for Gabriel Brooks

Key filing fact

Gabriel Brooks filed Form 4 for Solid Biosciences Inc. (SLDB) on 18 Feb 2026.

Key facts

This page summarizes Gabriel Brooks's Form 4 filing for Solid Biosciences Inc. (SLDB).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Feb 2026, 21:28.

Change

Previous filing in this sequence was filed on 06 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001997809 Primary reporting owner

Brooks Gabriel

Relationship: Chief Medical Officer
Address: C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN
Signature: /s/ Kimberly Cornwell as attorney-in-fact for Gabriel Brooks
Signature date: 18 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SLDB transaction

Common Stock

Options Exercise

Transaction value
Shares: +10,937
Change %: +13%
Price
Shares after: 95,029
Date: 13 Feb 2026
Ownership: Direct
Footnotes: F1

SLDB transaction

Common Stock

Sale

Transaction value: $0
Shares: 0
Change %: 0%
Price: $5.82
Shares after: 89,466
Date: 18 Feb 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SLDB transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -10,937
Change %: -33%
Price: $0.000000
Shares after: 21,876
Date: 13 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,937
Exercise price
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

Footnote F2

This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Dr. Brooks on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Brooks.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

Footnote F4

The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.